Teleflex Inc Hits 20-Day High After Major Business Sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy TFX?
Source: seekingalpha
Teleflex Inc experienced a significant price increase of 9.00%, reaching a 20-day high amid recent market fluctuations.
The company announced the sale of its Acute Care, Interventional Urology, and OEM businesses for $2.03 billion, aiming to optimize its portfolio and enhance competitiveness in critical healthcare markets. This strategic move is expected to provide Teleflex with approximately $1.8 billion in net proceeds, which will be used for share repurchases and debt reduction.
This transaction not only improves Teleflex's financial flexibility but also allows the company to focus on its core markets, potentially leading to mid-single-digit growth. Investors are optimistic about the long-term value creation resulting from this strategic restructuring.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFX
Wall Street analysts forecast TFX stock price to rise
7 Analyst Rating
1 Buy
5 Hold
1 Sell
Hold
Current: 122.930
Low
122.00
Averages
136.20
High
155.00
Current: 122.930
Low
122.00
Averages
136.20
High
155.00
About TFX
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teleflex Q4 2025 Earnings Call Insights
- Strategic Transformation Progress: Teleflex is undergoing a significant business transformation, planning to utilize approximately $1.8 billion in net proceeds from the sale of its Acute Care, Interventional Urology, and OEM businesses to support a $1 billion share repurchase and reduce debt, thereby enhancing financial flexibility and market competitiveness.
- 2026 Performance Outlook: Management expects adjusted EPS for 2026 to range between $6.25 and $6.55, despite anticipating a $90 million negative impact from stranded costs, indicating confidence in future growth and suggesting a clearer financial profile post-restructuring.
- Financial Results Highlights: For 2025, adjusted EPS was $6.98, reflecting an 8.7% year-over-year increase, while the adjusted gross margin stood at 63.7%, showing a decline due to tariffs and acquisitions, highlighting challenges in cost control and profitability.
- Market Reaction and Risks: Analysts expressed caution regarding management's guidance, focusing on stranded costs and restructuring impacts; while management remains optimistic about mid-term growth, they must navigate integration risks and tariff uncertainties.
See More
Teleflex (TFX) Q4 2025 Earnings Call Transcript
See More
Teleflex Stock Drops 2.3% Following Q4 Results That Fall Short of Expectations
- Teleflex Shares Decline: Teleflex shares fell by 2.3% following the release of their Q4 results.
- Missed Estimates: The company's performance did not meet analysts' expectations, contributing to the drop in share value.
See More
Teleflex Declares Quarterly Dividend of $0.34
- Quarterly Dividend Announcement: Teleflex has declared a quarterly dividend of $0.34 per share, consistent with previous distributions, indicating the company's stable cash flow and commitment to shareholder returns.
- Payment Schedule: The dividend will be payable on March 31, with a record date of March 6 and an ex-dividend date also set for March 6, ensuring shareholders receive their earnings promptly.
- Dividend Growth Potential: According to Teleflex's dividend scorecard and yield chart, the company shows a positive trend in dividend growth, reflecting its ongoing profitability and competitive position in the medical device industry.
- Market Reaction Expectations: While the current dividend level remains unchanged, investors maintain a cautiously optimistic outlook on Teleflex's future performance, particularly ahead of the upcoming Q4 2025 earnings report.
See More
Teleflex Reports Significant Q4 Net Loss Expansion
- Widened Net Loss: Teleflex reported a net loss of $714.33 million for Q4, translating to $16.15 per share, a significant increase from a loss of $136.66 million or $2.93 per share in the same quarter last year, indicating escalating financial pressures on the company.
- Loss from Continuing Operations: The loss from continuing operations was $0.08 per share, contrasting sharply with an income of $0.77 per share in the previous year, reflecting a significant decline in profitability from core operations, which may undermine investor confidence.
- Revenue Growth: Despite the widening losses, Teleflex's net revenues increased from $442.01 million to $568.98 million year-over-year, marking a 28.8% growth, suggesting some resilience in market demand.
- Future Outlook: The company projects earnings from continuing operations for fiscal 2026 to range between $2.90 and $3.20 per share, with adjusted earnings expected between $6.25 and $6.55 per share, alongside a revenue growth forecast of 14.4% to 15.4%, indicating cautious optimism for future performance.
See More
Teleflex to Host Q4 2025 Earnings Call on February 26, 2026
- Earnings Call Announcement: Teleflex Inc will host a conference call on February 26, 2026, at 8:00 AM ET to discuss its Q4 2025 earnings results, aiming to provide investors with insights into the company's financial performance and future outlook.
- Access Information: Investors can access the live webcast by visiting the company's investor relations page, or by dialing 1 800 770 2030 for US participants and 1 609 800 9909 for international participants, ensuring broad investor engagement.
- Conference ID Details: The conference ID for this call is 69028, which will help participants identify the meeting when dialing in, thereby enhancing the organization and efficiency of the call.
- Source Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect those of Nasdaq, Inc., reminding investors to exercise caution when interpreting the information.
See More
Teleflex Q4 2025 Earnings Call Insights
- Strategic Transformation Progress: Teleflex is undergoing a significant business transformation, planning to utilize approximately $1.8 billion in net proceeds from the sale of its Acute Care, Interventional Urology, and OEM businesses to support a $1 billion share repurchase and reduce debt, thereby enhancing financial flexibility and market competitiveness.
- 2026 Performance Outlook: Management expects adjusted EPS for 2026 to range between $6.25 and $6.55, despite anticipating a $90 million negative impact from stranded costs, indicating confidence in future growth and suggesting a clearer financial profile post-restructuring.
- Financial Results Highlights: For 2025, adjusted EPS was $6.98, reflecting an 8.7% year-over-year increase, while the adjusted gross margin stood at 63.7%, showing a decline due to tariffs and acquisitions, highlighting challenges in cost control and profitability.
- Market Reaction and Risks: Analysts expressed caution regarding management's guidance, focusing on stranded costs and restructuring impacts; while management remains optimistic about mid-term growth, they must navigate integration risks and tariff uncertainties.
See More
Teleflex (TFX) Q4 2025 Earnings Call Transcript
See More
Teleflex Stock Drops 2.3% Following Q4 Results That Fall Short of Expectations
- Teleflex Shares Decline: Teleflex shares fell by 2.3% following the release of their Q4 results.
- Missed Estimates: The company's performance did not meet analysts' expectations, contributing to the drop in share value.
See More
Teleflex Declares Quarterly Dividend of $0.34
- Quarterly Dividend Announcement: Teleflex has declared a quarterly dividend of $0.34 per share, consistent with previous distributions, indicating the company's stable cash flow and commitment to shareholder returns.
- Payment Schedule: The dividend will be payable on March 31, with a record date of March 6 and an ex-dividend date also set for March 6, ensuring shareholders receive their earnings promptly.
- Dividend Growth Potential: According to Teleflex's dividend scorecard and yield chart, the company shows a positive trend in dividend growth, reflecting its ongoing profitability and competitive position in the medical device industry.
- Market Reaction Expectations: While the current dividend level remains unchanged, investors maintain a cautiously optimistic outlook on Teleflex's future performance, particularly ahead of the upcoming Q4 2025 earnings report.
See More
Teleflex Reports Significant Q4 Net Loss Expansion
- Widened Net Loss: Teleflex reported a net loss of $714.33 million for Q4, translating to $16.15 per share, a significant increase from a loss of $136.66 million or $2.93 per share in the same quarter last year, indicating escalating financial pressures on the company.
- Loss from Continuing Operations: The loss from continuing operations was $0.08 per share, contrasting sharply with an income of $0.77 per share in the previous year, reflecting a significant decline in profitability from core operations, which may undermine investor confidence.
- Revenue Growth: Despite the widening losses, Teleflex's net revenues increased from $442.01 million to $568.98 million year-over-year, marking a 28.8% growth, suggesting some resilience in market demand.
- Future Outlook: The company projects earnings from continuing operations for fiscal 2026 to range between $2.90 and $3.20 per share, with adjusted earnings expected between $6.25 and $6.55 per share, alongside a revenue growth forecast of 14.4% to 15.4%, indicating cautious optimism for future performance.
See More
Teleflex to Host Q4 2025 Earnings Call on February 26, 2026
- Earnings Call Announcement: Teleflex Inc will host a conference call on February 26, 2026, at 8:00 AM ET to discuss its Q4 2025 earnings results, aiming to provide investors with insights into the company's financial performance and future outlook.
- Access Information: Investors can access the live webcast by visiting the company's investor relations page, or by dialing 1 800 770 2030 for US participants and 1 609 800 9909 for international participants, ensuring broad investor engagement.
- Conference ID Details: The conference ID for this call is 69028, which will help participants identify the meeting when dialing in, thereby enhancing the organization and efficiency of the call.
- Source Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect those of Nasdaq, Inc., reminding investors to exercise caution when interpreting the information.
See More
